- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00560989
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis
Shared Genetic Susceptibility in CBD and Sarcoidosis
Study Overview
Status
Conditions
Detailed Description
CBD and sarcoidosis are granulomatous lung diseases that are caused by an abnormal immune response. While CBD is known to develop from exposure to the industrial product beryllium, the cause of sarcoidosis remains undetermined. CBD occurs in 2 to 16% of people exposed to beryllium and varies in severity of symptoms. People with sarcoidosis often show very minor symptoms. However, certain variables have been associated with the more severe forms of disease. These variables include black race, onset over the age of 40, involvement of more than three affected organs, and presence of more serious lung disease. When serious symptoms of sarcoidosis occur, clinical and pathological appearances of CBD and sarcoidosis are often hard to distinguish. Symptoms common to both diseases include fever, chest pain, weight loss, night sweats, fatigue, and presence of granulomas on the lungs. The fact that the severity of both diseases varies greatly among those affected points to possible genetic involvement. The genetic basis being analyzed in this study begins with the similar immune responses in the development of both diseases, specifically involving human leukocyte antigen (HLA) gene products. The purpose of this study is to identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.
This study will utilize a novel technique, known as a genome-wide scan. The study will examine previously collected DNA samples from participants in a previous NIH study, A Case Control Etiologic Study of Sarcoidosis (ACCESS), and from participants with CBD recruited at the National Jewish Medical and Research Center. Using the genome scans, researchers will compare genetic regions of people with CBD versus people without CBD who have been exposed to beryllium. The same approach will be used to define genetic regions associated with sarcoidosis. Genome control methods will be used to account for population stratification in both the CBD and sarcoidosis populations. Researchers will compare data between diseased and healthy control groups and between CBD and sarcoidosis groups to identify shared genetic regions relevant to disease development. A second genome scan involving two larger populations of CBD and sarcoidosis cases and controls will be conducted to confirm the association of these regions with both diseases.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Medical and Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Has previously participated in beryllium studies conducted by Dr. Lisa Maier
- Agrees to allow the use of personal medical records and genetic material for future research by study officials
Exclusion Criteria:
- Will not consent for use of DNA for research purposes or for storage
- Any beryllium or sarcoidosis DNA specimens without an optical density of 260/280 nm, ratio between 1.8 and 2.0, or with an insufficient quantity of DNA for analysis purposes
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
1
CBD cases
|
2
Beryllium-exposed, non-diseased control subjects
|
3
Sarcoidosis cases
|
4
Sarcoidosis control subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Shared genetic regions associated with the risk of the granulomatous diseases CBD and sarcoidosis
Time Frame: Measured at completion of genetic analysis
|
Measured at completion of genetic analysis
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Genetic/chromosomal regions associated with CBD and sarcoidosis
Time Frame: Measured at completion of genetic analysis
|
Measured at completion of genetic analysis
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lisa A. Maier, MD, MSPH, National Jewish Health
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1382
- R21HL081766 (U.S. NIH Grant/Contract)
- R21HL081766-01A2 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoidosis
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
University Hospital, LilleTerminated
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Heart Center Leipzig - University HospitalRecruiting
-
British Columbia Cancer AgencyApproved for marketing
-
University of EdinburghUnknown
-
Mayo ClinicCompleted
-
Pusan National University Yangsan HospitalCompletedMuscular SarcoidosisKorea, Republic of
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); Ontario Ministry of Health and...Recruiting